0.288
0.00 (-0.69%)
| Penutupan Terdahulu | 0.290 |
| Buka | 0.300 |
| Jumlah Dagangan | 188,752 |
| Purata Dagangan (3B) | 307,529 |
| Modal Pasaran | 9,709,200 |
| Harga / Jualan (P/S) | 2.42 |
| Harga / Buku (P/B) | 0.200 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| Margin Operasi (TTM) | -17,009.68% |
| EPS Cair (TTM) | -1.17 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -89.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.03% |
| Nisbah Semasa (MRQ) | 4.43 |
| Aliran Tunai Operasi (OCF TTM) | -29.41 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -16.91 M |
| Pulangan Atas Aset (ROA TTM) | -33.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -56.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Menurun | Bercampur |
| Medical Devices (Global) | Menurun | Bercampur | |
| Stok | Co-Diagnostics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | 1.50 |
|
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.00% |
| % Dimiliki oleh Institusi | 17.44% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Private Advisory Group Llc | 31 Mar 2025 | 1,181,633 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (D. Boral Capital, 3,372.22%) | Beli |
| Median | 5.50 (1,809.72%) | |
| Rendah | 1.00 (HC Wainwright & Co., 247.22%) | Pegang |
| Purata | 5.50 (1,809.72%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 0.346 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 28 Apr 2025 | 10.00 (3,372.22%) | Beli | 0.371 |
| HC Wainwright & Co. | 28 Mar 2025 | 1.00 (247.22%) | Pegang | 0.320 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 May 2025 | Pengumuman | Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference |
| 08 May 2025 | Pengumuman | Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results |
| 29 Apr 2025 | Pengumuman | Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast |
| 27 Mar 2025 | Pengumuman | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results |
| 13 Mar 2025 | Pengumuman | Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |